The invention provides a
toxoplasma gondii attenuated strain RH [
delta] ku80 [
delta] hxgprt capable of enhancing a macrophage function. The TUB1 is TIR1-3FLAG, and the SAG1 is CAT; [
delta] OMPDC:: dhfr-ts: dhfr, [delta] OMPDC:: dhfr; [delta] UP:: dh fr-ts: hxgprt ([delta] OMPDC [delta] UP). The low virulent strain delta OMPDC delta UP is obtained by knocking out OMPDC and UP genes from a TIR1
insect strain by using a
CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated 9) technology. The strain can effectively enhance macrophage functions including phagocytic ability, proinflammatory factor
secretion and the like. The
insect strain construction process comprises
plasmid construction, homologous template amplification and positive
insect strain screening and identification. In order to systematically evaluate the
immune regulation efficiency, the regulation effect of the
attenuated strain on proliferation, migration,
chemotaxis,
active oxygen, phagocytic function and
apoptosis of macrophages is quantitatively analyzed by adopting multi-
dimensional analysis technologies such as a CCK-8 method, a
cell scratch experiment and a Transwell migration model. Furthermore, the
mRNA expression level of inflammatory cytokines after
polypide infection with macrophages is determined through qPCR, and a theoretical basis and
technical support are provided for clarification of an immunoregulation network of
toxoplasma gondii-host interaction and development of vaccine design based on low virulent strains.